Anzeige
Meldung des Tages: Breaking News: Diese Goldaktie zündet den Turbo – Bohrstart bei Ceibal HEUTE verkündet!

Neurocrine Biosc. News

Aktie
WKN:  900964 ISIN:  US64125C1099 US-Symbol:  NBIX Branche:  Pharmazeutika Land:  USA
130,68 $
+0,83 $
+0,64%
113,29 € 17.03.26
Depot/Watchlist
Marktkapitalisierung *
12,30 Mrd. €
Streubesitz
-
KGV
20,38
Nachhaltigkeits-Score
40 %
Index-Zuordnung
-
Weiter aufwärts? Long handeln - Jetzt mit Hebel 5,89: MN4HCE
Werbung

Neurocrine Biosciences News

17.03.26 - PR Newswire
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer PR Newswire
10.03.26 - PR Newswire
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum PR Newswire
06.03.26 - PR Newswire
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX)
BetterInvesting™ Magazine Update on Equifax Inc. (NYSE: EFX) and Neurocrine Bio In. (NASDAQ: NBIX) PR Newswire
24.02.26 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
Neurocrine Biosciences to Present at Upcoming Investor Conferences in March PR Newswire
11.02.26 - PR Newswire
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
Neurocrine Biosciences Reports Fourth-​Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026 PR Newswire
26.01.26 - PR Newswire
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia PR Newswire
21.01.26 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results PR Newswire
15.01.26 - PR Newswire
Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
Neurocrine Biosciences Presents Head-​to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR PR Newswire
05.01.26 - PR Newswire
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
22.12.25 - PR Newswire
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy PR Newswire
16.12.25 - PR Newswire
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology PR Newswire
09.12.25 - PR Newswire
Neurocrine Biosciences to Host R&D Day on December 16
Neurocrine Biosciences to Host R&D Day on December 16 PR Newswire
20.11.25 - PR Newswire
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) Capsules
Neurocrine Biosciences Announces Publication of Landmark Narrative Review on FDA-​Approved VMAT2 Inhibitors Demonstrating Unique Profile of INGREZZA® (valbenazine) ...
11.11.25 - PR Newswire
Neurocrine Biosciences to Present at Upcoming Investor Conferences
Neurocrine Biosciences to Present at Upcoming Investor Conferences PR Newswire
10.11.25 - PR Newswire
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder
Neurocrine Biosciences Provides Update on Phase 2 Study of NBI-1070770 in Adults with Major Depressive Disorder PR Newswire
28.10.25 - PR Newswire
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results
Neurocrine Biosciences Reports Third Quarter 2025 Financial Results PR Newswire
17.10.25 - PR Newswire
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules PR ...
07.10.25 - PR Newswire
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results PR Newswire
06.10.25 - PR Newswire
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise PR Newswire
06.10.25 - PR Newswire
Neurocrine Biosciences Presents New Three-Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for Huntington's Disease Chorea
Neurocrine Biosciences Presents New Three-​Year Data Demonstrating Sustained Clinical Benefits and Established Safety Profile of INGREZZA® (valbenazine) Capsules for ...

Newssuche

Videos

newspaper
16.03.26 +1,50%
Technical Trading: 82 Prozent Trefferquote
S&P 500 Long Typ: Open End Turbo WKN: VG93RW Hebel: 5 Laufzeit: OpenEnd Einstieg: Market ... Mehr »